We confirmed that exogenous recombinant Wnt3a increased the clonogenic capacity of differentiated (Wnt−/lo and CD133−/lo) CRC cells in a dose-dependent manner (Fig. 4a). Here, WNT3A is linked to colorectal carcinoma.